Press Releases

Date	Title and Summary	View
Toggle Summary Apr 25, 2019	Oxford Immunotec Schedules First Quarter 2019 Earnings Release and Conference Call for May 9, 2019 OXFORD, United Kingdom and MARLBOROUGH, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2019 financial results before the open of the market on	View HTML PDF Version
Toggle Summary Mar 28, 2019	Oxford Immunotec Announces New Initiative to Bring the Benefit of Modern Tuberculosis Testing to the Russian Federation OXFORD, United Kingdom and MARLBOROUGH, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced a new local production initiative to bring the benefits of the T-SPOT ® .	View HTML PDF Version
Toggle Summary Mar 21, 2019	Oxford Immunotec Announces Chief Financial Officer Transition OXFORD, United Kingdom and MARLBOROUGH, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that Richard Altieri, the Company’s Chief Financial Officer (CFO), will retire on April 30, 2019.	View HTML PDF Version
Toggle Summary Mar 11, 2019	Oxford Immunotec Reports Fourth Quarter and Full Year 2018 Financial Results OXFORD, United Kingdom and MARLBOROUGH, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, today announced fourth quarter and full year 2018 financial results.	View HTML PDF Version
Toggle Summary Mar 05, 2019	Oxford Immunotec to Participate in Two Upcoming Investor Conferences OXFORD, United Kingdom and MARLBOROUGH, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to present at the following upcoming investor	View HTML PDF Version
Toggle Summary Feb 19, 2019	Oxford Immunotec Schedules Fourth Quarter and Full Year 2018 Earnings Release and Conference Call for March 11, 2019 OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release fourth quarter and full year 2018 financial results after the close of the	View HTML PDF Version
Toggle Summary Jan 06, 2019	Oxford Immunotec Announces Board Approval of $100 Million Share Repurchase Program and Reaffirms Growth Expectations for Fourth Quarter 2018 OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 06, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that its Board of Directors has approved a share purchase program, which would involve the purchase	View HTML PDF Version
Toggle Summary Jan 02, 2019	Oxford Immunotec to Present at the 37th Annual J.P. Morgan Healthcare Conference OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the 37th Annual J.P.	View HTML PDF Version
Toggle Summary Dec 07, 2018	Oxford Immunotec Announces Regulatory Acceptance of T-Cell Select™ in China OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced regulatory acceptance of the T-Cell Select kit by the China Food and Drug Administration (CFDA).	View HTML PDF Version
Toggle Summary Nov 26, 2018	Oxford Immunotec to Participate in Two Investor Conferences This Week OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to present at the following investor	View HTML PDF Version